Autologous anti-BCMA chimeric antigen receptor (CAR) T-cell therapy: patient T lymphocytes are genetically engineered to express a CAR targeting BCMA and infused intravenously (3+3 dose escalation, up to 6×10^6 CAR-T cells/kg). CAR engagement activates T-cell cytotoxicity (degranulation, cytokine release, proliferation) to eliminate BCMA-positive myeloma cells. The construct includes EGFR expression as a built-in safety/control feature.